

5 May 2022

Diaceutics PLC

("Diaceutics" or "the Company")

Contract win

US\$1m+ contract with global pharma company for data feed from the DXRX platform

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, is pleased to announce it has secured a five-year, multi-product subscription contract with a top 30 global pharma company, to deliver customised data insights via the DXRX platform. The total contract value is in excess of \$1m spread across five years and subject to certain milestones, significantly expanding Diaceutics' existing relationship with the company and setting Diaceutics up for future opportunities with the client.

The contract will see Diaceutics deliver a core set of real-world data and insights on lab test results that identify physicians who are treating patients in their target cohorts. The demand for biomarker test results and interpretation customised to the client's needs in oncology was a key value proposition for DXRX Signal, one of the primary products being taken.

This contract further demonstrates the applicability and demand for new products enabled by the DXRX platform and supports the move towards enhanced multi-year recurring revenues, a key strategy for the Company going forward.

Ryan Keeling, CIO and Co-Founder of Diaceutics PLC, commented:

"This multi-product, multi-year auto renew contract speaks to how our DXRX platform spans the full diagnostic commercialisation pathway; in this instance providing our client with the insights they need to better engage with prescribers to choose their therapy.

"We are encouraged by the pace of deal flow for our newly launched data feeds, which are proving valuable entry points for both new and existing customers onto the DXRX platform."

Enquiries:

Diaceutics PLC

Nick Roberts, Chief Financial Officer

Via Alma PR

Ryan Keeling, Chief Innovation Officer

Stifel Nicolaus Europe Limited (Nomad & Broker)

Tel: +44 (0)20 7710 7600

Ben Maddison, Stewart Wallace, Nick Adams

Alma PR

Tel: +44(0)20 3405 0205

Caroline Forde, Kieran Breheny, Matthew Young

diaceutics@almapr.co.uk

About Diaceutics

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

Diaceutics' data capability is one of the three key value drivers it has integrated into its unique DXRX platform alongside its global Lab network and product suite tailored for Precision testing.

share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

CNTFZGGKNDFGZZM